Form 4: Korro Bio CSO Granted 21,715 RSUs

Korro Bio's Chief Scientific Officer, Vincent Loic A, was granted 21,715 restricted stock units vesting in 2026.

Summary

• Vincent Loic A, Chief Scientific Officer of Korro Bio, Inc. (KRRO), was granted 21,715 shares of common stock.
• The transaction date for this grant was December 15, 2025.
• These shares represent Restricted Stock Units (RSUs) issued under the Issuer's 2023 Stock Option and Incentive Plan.
• The RSUs will vest in two equal tranches: 50% on June 15, 2026, and the remaining 50% on December 15, 2026.
• Vesting is contingent upon the reporting person maintaining a continuous Service Relationship with the company through each vesting date.

Sentiment

Score: 7

Explanation: The RSU grant is a positive signal for executive retention and alignment of interests with shareholders, which is generally viewed favorably, though it is a routine compensation event.

Positives

• The RSU grant aligns the Chief Scientific Officer's interests with long-term shareholder value, as the value of the compensation is tied to the company's stock performance.
• This type of equity compensation serves as a retention mechanism, incentivizing the executive to remain with the company through the vesting periods.

Negatives

• The issuance of new shares upon vesting will result in a minor dilution for existing shareholders, though this is a standard aspect of equity compensation plans.

Risks

• The vesting of the granted RSUs is subject to the reporting person maintaining a continuous Service Relationship with Korro Bio, Inc. through the specified vesting dates.

Future Outlook

The future outlook indicates that the Chief Scientific Officer's compensation is tied to the company's performance and continued service through at least December 2026, suggesting a commitment to long-term executive retention and alignment.

Industry Context

The grant of restricted stock units to a Chief Scientific Officer is a common and standard practice in the biotechnology and pharmaceutical industries for executive compensation. It is designed to attract, retain, and motivate key scientific leadership by aligning their financial interests with the long-term success and stock performance of the company.

Comparison to Industry Standards

• The RSU grant to a Chief Scientific Officer is a standard form of executive compensation widely adopted across the biotechnology sector, comparable to practices at companies like Moderna, BioNTech, or CRISPR Therapeutics, which frequently use equity awards to incentivize and retain key scientific and executive talent.
• The vesting schedule, typically over several years and contingent on continued service, is also a common structure designed to promote long-term commitment and performance, consistent with industry benchmarks for executive equity grants.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor potential for dilution upon vesting, but benefits from increased executive alignment and retention.
• Employees: Demonstrates the company's commitment to executive compensation and retention strategies, potentially boosting morale and confidence in leadership.

Next Steps

• The company will proceed with the vesting of the RSUs on June 15, 2026, and December 15, 2026, contingent on the Chief Scientific Officer's continuous service.

Key Dates

Keywords

Korro Bio, KRRO, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Form 4, Equity Grant, Chief Scientific Officer